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Abstract
It is currently unknown how mucosal adjuvants cause induction of secretory immunoglobulin A (IgA), and how T cell-
dependent (TD) or -independent (TI) pathways might be involved. Mucosal dendritic cells (DCs) are the primary antigen
presenting cells driving TI IgA synthesis, by producing a proliferation-inducing ligand (APRIL), B cell activating factor (BAFF),
Retinoic Acid (RA), TGF-b or nitric oxide (NO). We hypothesized that the mucosal adjuvant Cholera Toxin subunit B (CTB)
could imprint non-mucosal DCs to induce IgA synthesis, and studied the mechanism of its induction. In vitro, CTB-treated
bone marrow derived DCs primed for IgA production by B cells without the help of T cells, yet required co-signaling by
different Toll-like receptor (TLR) ligands acting via the MyD88 pathway. CTB-DC induced IgA production was blocked in vitro
or in vivo when RA receptor antagonist, TGF-b signaling inhibitor or neutralizing anti-TGF-b was added, demonstrating the
involvement of RA and TGF-b in promoting IgA responses. There was no major involvement for BAFF, APRIL or NO. This
study highlights that synergism between CTB and MyD88-dependent TLR signals selectively imprints a TI IgA-inducing
capacity in non-mucosal DCs, explaining how CTB acts as an IgA promoting adjuvant.
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Introduction
Secretory immunoglobulin A (SIgA) is abundantly present at
mucosal surfaces of the gastrointestinal and respiratory tract. Here,
SIgA, prevents pathogens and commensal bacteria from binding
to epithelial cells, it prevents ingested or inhaled allergens to cause
immunopathology and it neutralizes toxins, thus broadly acting to
maintain homeostasis in the gut and lung [1–4]. Inducing IgA
synthesis might be beneficial in a number of immune-mediated
mucosal diseases like asthma. Lack of IgA is associated with
increased rates of sensitization to inhaled and ingested allergens
[5,6], whereas adoptive transfer of allergen-specific IgA or IgA
producing B cells in mice can protect from allergic disease [7,8]. If
we are to exploit the full potential of IgA as an immunomodulatory
immunoglobulin in mucosal diseases such as asthma, we need to
understand better how IgA synthesis is regulated and how we can
promote the synthesis of IgA through the use of adjuvants.
IgA synthesis is regulated by both T cell-dependent (TD) and T
cell-independent (TI) pathways. In TD IgA synthesis, antigen
specific naı¨ve B cells differentiate into IgA+-committed B cells
upon stimulation by CD40L expressed on activated T cells and
TGF-b expressed by multiple cell types. Alternatively, TI IgA
synthesis is induced in polyclonal naı¨ve B cells by dendritic cell
(DC)- and epithelial cell- derived molecules, such as proliferation-
inducing ligand (APRIL), B cell activating factor (BAFF), Retinoic
Acid (RA), TGF-b or nitric oxide (NO) [9–11]. Mucosal DCs,
found in Peyer’s Patches (PP) and lamina propria of the gut or in
the lung epithelium and lamina propria [12], are the primary
antigen presenting cells that can drive TI (canonical) IgA class
switching. Importantly, mucosal conditioning of DCs occurs via
tissue-derived factors, such as RA and TGF-b, but also by
(commensal) bacteria expressing Toll-like receptor (TLR) ligands
[13–15].
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We hypothesized that there might exist mucosal adjuvants that
imprint non-mucosal DCs to stimulate humoral IgA responses
through instructive signals that closely mimick those found during
residence of mucosal DCs in their natural mucosal environment.
We focused on the TLR-independent molecule Cholera Toxin
subunit B (CTB), produced by the bacterium Vibrio cholerae.
Cholera toxin (CT) contains a toxic ADP-ribosyltransferase
subunit A, linked to a pentamer of non-toxic B carrier subunits.
CTB was shown to bind specifically to GM1-ganglioside (GM1), a
receptor expressed on the membrane of most types of epithelial
cells, but also on various hematopoietic cells. CTB is widely used
as a mucosal adjuvant, stimulating tolerance to co-administered
antigen [16,17]. In a mouse model, CTB enhanced IgA responses
against inhaled allergens [8]. Here we studied whether CTB can
prime non-mucosal DCs to induce IgA production, and whether
similar molecular signals are involved in the cellular communica-
tion between DCs and B cells as described for TI IgA synthesis
induced by mucosal PP DCs.
Results
CTB+LPS-primed Bone Marrow Derived DCs Promote IgA
Production in vitro
To study whether CTB could prime non-mucosal DCs to
induce IgA production, we employed an in vitro co-culture system
in which bone marrow derived (BM)-DCs were cultured with
splenic B cells (Balb/C background), in a one-to-one ratio for
seven days (adapted from [18]). DCs were grown in GM-CSF,
mainly generating inflammatory-type DCs. To address the impact
of TLR signaling and mucosal adjuvants on DC function, the DCs
were first exposed to LPS with or without CTB. Significant levels
of polyclonal IgA (,200 ng/ml) were measured in supernatant
when B cells were co-cultured with LPS (1 ng/ml)+CTB-pulsed
DCs, compared to low levels of IgA (,80 ng/ml) in the control
conditions CTB- or LPS-primed DCs. Interestingly, although BM-
DCs primed with 100 times more LPS (100 ng/ml; LPShi) were
able to induce a significant IgA production, the addition of CTB
during priming dramatically further enhanced the IgA production
by co-cultured B cells (Figure 1a). Surface IgA staining confirmed
the generation of IgA positive splenic B cells (,3-fold increase for
LPS+CTB condition) (data not shown). Similar data were
obtained when using naive B cells (CD432 splenocytes) (Figure
S1a) or BM-derived conventional DCs generated in the presence
of Flt3L (Figure S1b), suggesting these findings were not due to
expansion of a pre-existing memory IgA-class switched B cell
population or was unique to inflammatory DCs. IgA induction by
non-mucosal BM-DCs was compared to bona fide mucosal PP-
DCs, representing the natural IgA inducing capacity of cells
specialized in promoting this response. To obtain sufficient
amounts of PP-DCs, C57Bl/6 mice were first injected subcutane-
ously with a B16 Flt3-L secreting melanoma cell line [19] to
increase recovery of ex vivo DCs. The priming of BM-DC by
LPS+CTB resulted in non-mucosal-DCs that were as potent as
that of ex vivo purified mucosal DCs obtained from the PP
(Figure 1b). The ex vivo PP-DCs preparation contained ,4%
CD19+ B cells, which may harbor some memory IgA producing B
cells, potentially influencing the IgA levels found in these cultures.
However, there was evidence of active class switching in naı¨ve B
cells. In cultures with total B cells (CD19+) or with naı¨ve B cells
(CD432), the enzyme activation-induced deaminase (AID),
involved in antibody class switching, was upregulated in the
condition of LPS+CTB pulsed DCs (Figure S1c). As in general low
levels of other immunoglobulins (IgG1, IgG2a, IgE) were detected
in all conditions (Figure 1c), this shows that CTB has a
predominant IgA promoting effect. Addition of an adenylate
cyclase inhibitor did not affect the induction of IgA by LPS+CTB-
pulsed DCs, excluding the contribution of Cholera Toxin subunit
A traces in this process (data not shown). Importantly, B cells
exposed to CTB or LPS+CTB (either followed by culture with
mature DCs or not) did not produce IgA, indicating that CTB did
not act on B cells directly (data not shown).
These results were reproducible using cells obtained from mice
of both C57Bl/6 and Balb/C genetic background, although IgA
levels were generally (.3 fold) lower in C57Bl/6 cells (Figure 1a
vs 1b). Throughout the paper, cultures were done with cells
isolated from Balb/C mice, except for cultures with KO cells as
these mice are of C57Bl/6 background.
Figure 1. CTB/LPS-primed BM-DCs promote IgA production
in vitro. BM-derived DCs were cultured for 8 days with GMCSF, pulsed
overnight with PBS, LPS (1 ng/ml) +/2 CTB (10 mg/ml) or CTB alone,
and then co-cultured with splenic B cells (ratio 1:1) and anti-IgM Fab-
fragments (10 mg/ml). After 7 days, IgA levels were determined by
ELISA. (A) BM-DC and B cells of Balb/c background were used for the co-
culture. In addition to the conditions described, a high concentration
(100 ng/ml) of LPS was used to pulse the BM-DC (B) Besides BM-DC, PP-
DC were used to put in co-coculture with B cells (all of C57/Bl6
background) (C) In addition to IgA, also other Immunoglobulin isotypes
were measured in supernatant of cocultures (Balb/c) by ELISA.
Mean+sem of at least 5 individual experiments are shown. * P,0.05,
** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0059822.g001
IgA Induction by Cholera Toxin B-Dendritic Cells
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MyD88 Driven Pathways Synergize with CTB Priming to
Drive IgA Promoting DCs
The fact that CTB-primed DCs did not induce IgA production
by co-cultured B cells whereas CTB+LPS-primed DCs readily did,
suggests a synergistic effect of CTB- and LPS activated pathways
in instructing DCs to adopt a mucosal phenotype. LPS activates
the TLR4 receptor, which signals through the downstream
adaptor molecule MyD88. The IgA promoting effect of LPS+CTB
primed DCs was abrogated when wild type B cells and MyD88-
deficient DCs (C57Bl/6 background) were cultured together, even
when the high concentration LPS (100 ng/ml) was used, pointing
at a crucial involvement of MyD88 (Figure 2a).
Next we questioned whether co-activation of the DCs via other
Pattern Recognition Receptor (PRR) pathways was also able to
promote CTB-driven IgA induction by DCs. Therefore DCs were
stimulated with different TLR ligands (FLS1 (TLR2/6), poly I:C
(TLR3), LPS (TLR4), flagellin (TLR5), CL97 (TLR7/8), or CpG
(TLR9)), or non-TLR PRRs such as C-type lectin ligands (CTLs)
Zymosan (TLR2/Dectin) and Curdlan (Dectin-1) with or without
CTB, followed by co-cultures with splenic B cells (Balb/C).
Interestingly, high level microbial priming of BM-DCs by several
TLR ligands alone, e.g. LPS (high dose, 100 ng/ml)), FLS1, CL97
and CpG, was sufficient to induce IgA production (Figure 2b,
black bars). Importantly, CTB strongly further enhanced the IgA
induction by DCs primed with MyD88-dependent TLRs; but only
slightly or not at all for DCs primed with the MyD88-independent
TLR ligand (poly I:C) or the non-TLR-dependent CTLs
(Zymozan and Curdlan) (Figure 2b). Intriguingly, the IgA
inducing capacity of DCs primed by CpG was not further
enhanced by CTB, although TLR9 activity is also MyD88-
dependent.
Critical Involvement of DC-derived RA and TGF-b
Priming of non-mucosal BM-DCs with CTB in synergy with
MyD88-dependent TLR ligands leads to IgA-inducing DCs.
Several factors, including NO, RA, TGF-b, APRIL and BAFF can
promote IgA production at the intestinal mucosa [9]. To elucidate
whether the IgA inducing capacity of CTB-primed BM-DCs was
associated with one of these factors, we analyzed gene expression
profiles of RA synthesizing enzymes retinal dehydrogenase 1
(RALDH1) and 2 (RALDH2), inducible NO Synthetase (iNOS),
TGF-b, BAFF and APRIL in 24 hrs conditioned DCs by PCR
from 4 independent Balb/C DC cultures. RALDH1, RALDH2
and iNOS gene expression was slightly but significantly upregu-
lated in LPS-primed DCs 24 hrs post-pulsing, compared to
unpulsed DC. Interestingly, LPS+CTB-primed DCs which sup-
port IgA responses, express highly elevated levels of RALDH1 and
iNOS compared to the other conditions, while BAFF, APRIL and
TGF-b gene expression was equally expressed in all conditions
(Figure 3a). As LPS+CTB-primed DCs and CTB-DCs expressed
equal enhanced gene expression levels of RALDH1, we also
analyzed ALDEFLUOR activity in both GMCSF-cultured and in
FLT3-L-cultured DCs after exposure to CTB or LPS+CTB. In
FLT3-L cultured DCs we observed a clear upregulation of
ALDEFLUOR activity after priming with LPS+CTB, but not in
response CTB only or to the other control conditions (Figure 3b).
This correlated well with their capacity to induce IgA (Figure S1b)
and suggests a differential capacity to enhance ALDEFLUOR
activity despite equal enhanced RALDH1 gene expression
comparing LPS+CTB and CTB only. Although the activity was
most pronounced in CD11b+ DCs, the same trend was visible in
CD11b2 DCs. Surprisingly, GMSCF-cultured DCs did not show
any enhanced ALDEFLUOR activity in response to LPS+CTB
(Figure 3b). But this may be explained by the fact that the basal
levels of ALDEFLUOR activity were already extremely high (MFI
100 fold higher compared to Flt3-L DCs) in unprimed GM-CSF
DCs, making it difficult to measure any further enhancement. This
is probably the result of the continuous exposure to GM-CSF as
shown by Yokota et al [20]. Of note, we observed an abolished
IgA production by LPS+CTB-primed DCs in medium with UV-
irradiated FCS (data not shown), in which serum-derived retinoids
were destroyed, confirming an underlying role for DC metabolism
of retinal to RA in their capacity to induce IgA in B cells. This
mechanism has similarly been described for mesenteric lymph
node DCs, at least with respect to the RA-dependent induction of
gut homing receptors on T cells [21].
Gene expression of TGF-b was not enhanced, but regulation
may occur at the posttranscriptional level. Furthermore, our
previous studies point towards an important role for TGF-b in
CTB-driven IgA-dependent protective responses against AAI [8].
Subsequent protein expression of TGF-b (measured by, yet
inactive, LAP) was slightly but consequently increased in CTB-
primed DCs, compared to control DCs (Figure S2).
Figure 2. MyD88 driven pathways synergize with CTB priming
to drive IgA promoting. DCs. (A) BM-DCs from WT or MyD882/2 mice
(C57/Bl6 background) were pulsed with PBS, LPShi (100 ng/ml), LPShi+
CTB (10 mg/ml) or CTB alone and co-cultured as described at Figure 1.
(B) BM-DCs were pulsed with PBS, or different TLR ligands (Poly I:C
25 mg/ml, LPS 100 ng/ml, Flagellin 1 mg/ml, FLS1 10 mg/ml, Cl97 1 mg/
ml, CpG 2.5 mg/ml) or CTLs (Zymozan 10 mg/ml, Curdlan 150 mg/ml)
with and without CTB, followed by co-cultures with splenic B cells. Data
of one representative experiment out of three is shown. * P,0.05, **
P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0059822.g002
IgA Induction by Cholera Toxin B-Dendritic Cells
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To study the functional involvement of these molecules, in vitro
experiments were performed in which either the cells were
genetically deficient for certain critical mediators or chemical
inhibitors were added. When the RA receptor was blocked by the
antagonist LE135, we consistently observed a partial inhibition of
IgA production by B cells cultured with LPS+CTB-DC
(Figure 4a). RA receptor inhibitor LE540 or Citral, which block
RA production through blockade of the enzymatic activity,
resulted in similar inhibition (data not shown). Blocking TGF-b
signaling, using SB-431542, significantly decreased (2–4 fold) IgA
production by LPS+CTB-primed DCs (Figure 4b). Importantly,
when both TGF-b signaling and signaling via RA were blocked,
the IgA response was completely abrogated (Figure 4b). Equal
proliferation of CFSE-labeled B cells and similar IgM levels were
found for all conditions (data not shown) excluding cytotoxic
effects of the inhibitors.
Although mRNA expression for iNOS was strongly elevated in
LPS+CTB-primed DCs, blocking NO synthesis by the inhibitor L-
NIL only had a marginal effect on IgA production (data not
shown). Furthermore, co-cultures of iNOS2/2 BM-DCs and WT
B cells resulted in similar IgA levels as in WT cultures (Figure 4c),
indicating that iNOS is not involved in CTB-induced IgA
production in our model. Blocking either BAFF and/or BAFFR3
did not affect CTB-induced IgA production (Figure S3a). APRIL
Figure 3. Expression of candidate IgA inducing molecules of BM-DCs. (A) BM-DCs were cultured as described previously and pulsed with
PBS, LPS (1 ng/ml) +/2 CTB (10 mg/ml) or CTB alone. After 24 hrs the following gene expression was analyzed (A) RALDH1, RALDH2, iNOS, BAFF,
APRIL and TGF-b. Expression is normalized against the house keeping gene GAPDH and displayed as relative to conventional unpulsed BM-DCs.
Mean+sem of 4 indvidual BM-DC cultures are shown. (B) BM-DCs were generated by culture in GM-CSF or Flt3-L, and pulsed as described. After 24
hours, cells were washed and stained for ALDEFLUOR activity (according to the instructions of the manufacturer), CD11c, CD11b and MHCII
expression and analyzed by flowcytometry. The results are a mean+sem from 4 independent experiments. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0059822.g003
IgA Induction by Cholera Toxin B-Dendritic Cells
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gene expression was not induced in LPS+CTB-primed DCs,
however APRIL may also be regulated during translation [22].
Therefore, we investigated a possible role for APRIL in mice
lacking both receptors for APRIL, the Transmembrane activator
and CAML-interactor (TACI) and B cell maturation antigen
(BCMA) double deficient mice. Of note, TACI and BCMA are
also receptors for BAFF, but BAFF can still signal through a third
receptor, the BAFF3 receptor. Surprisingly, co-cultures of TACI/
BCMA2/2 B cells and LPS/CTB-primed DCs resulted in strongly
elevated levels of IgA (.1000 ng/ml) compared to WT control
cultures (Figure S3b). These results may suggest that signaling via
the receptors TACI and BCMA has a negative influence rather
than a promoting function. Alternatively, these results may be
explained by highly proliferating cells in which the process of class
switching was prevented.
In summary, these data support a dominant role for both TGF-
b and RA in driving CTB-induced IgA responses in vitro.
Ex vivo CTB-pulsed DCs Promote IgA Responses in the
Lungs via RA and TGF-b
In vitro, synergistic signaling of CTB and MyD88 conditioned
non-mucosal DCs to promote IgA responses, via TGF-b and RA.
We wondered whether it was possible to prime DC in vivo, and
stimulate IgA responses. To address this question, we decided to
administer CTB in the lungs of anesthetized mice via aspiration
thought the glottis. Using the pulmonary route of delivery allows
consistent delivery of CTB without the need of breeching any
physiological barriers through injections. Needle injection through
the skin causes damage and inevitable release of damage
associated molecular patterns that could influence IgA induction.
A single administration of CTB along with the OVA to the
airways resulted in increased IgA production by lung B cells that
where isolated one day after the last OVA challenge (Figure 5a).
Previously, in a paper focusing on OVA-induced experimental
asthma, we published that adoptive transfer of the in vitro
generated OVA/CTB-pulsed BM-DC results in increased IgA
responses in vivo [8]. The OVA (Worthington) used as a model
antigen here, contains a sufficient amount of LPS to provide for
the necessary MyD88 signaling (Figure S4). Furthermore, we
studied whether DCs are prominently targeted by CTB when
administered in the airways, as many hematopoietic cells express
GM1 [16]. AF488-labeled CTB with or without OVA was
administered into the airways of naı¨ve mice, after 36 hrs the
AF488hi cells present in the lung-draining lymph nodes were
analyzed, using markers that specifically identify the different DC
subsets and other APCs (Figure 5b) The vast majority of the
AF488hi cells (almost 80%) consisted of DCs; both CD11b+ and
CD11b2 migratory DCs (MHCIIhiCD11chi), resident DCs
(MHCIIintCD11chi), and some pDCs (MHCloCD11-
cintB220+CD11b2) (Figure 5c). Some B cells (MHCIIhiB220+,
,10%) and only a few T cells (CD3+) and macrophages (,1%,
MHCIIloCD11cintCD11b+B2202) had taken up the labeled CTB
(data not shown). The remaining non-migrated AF-488hi cells left
behind in the lungs also mainly consisted of DCs, containing equal
percentages of resident CD11b+ and CD11b2 DCs
(MHCII+CD11c+) (data not shown).
As these experiments revealed that CTB also targeted predom-
inantly the DC population in vivo and similarly led to increased
IgA induction in the lung, we next aimed to investigate whether
CTB modified DC function in vivo as it did in vitro. Therefore,
CTB +/2 OVA was instilled in the airways of mice and the RA
producing capacity of different DC subsets was studied by flow
cytometry at locations of potential interaction between DCs and B
cells, i.e. the draining Mediastinal LN (MedLN) and the lung.
Aldehyde dehydrogenase (ALDH, catalyzes oxidation of retinal
into RA) activity of DCs was determined using ALDEFluor
staining kit. Both CD103+ and CD11b+ migratory DC subsets
found in the MedLN showed ALDH enzyme activity, ,35% and
,45% of the DCs subsets respectively. But upon OVA+CTB
instillation, a significantly higher percentage of migratory CD11b+
DCs (.60%) were positive in the ALDEFluor assay compared to
CD11b+ DCs (,50%) from control mice not treated with
OVA+CTB (Figure 5d, for representative dotplots of ALDE-
Fluor expression see Figure S5a/b). In contrast, there were
considerably less DCs left behind in the lung that expressed
Figure 4. In vitro, RA and TGF-b are responsible for IgA
induction by CTB-primed DCs. BM-DCs were pulsed with PBS, LPS
(100 ng/ml), LPS+ CTB (10 mg/ml) or CTB alone and co-cultured as
described at Figure 1. (A) During the co-culture the RA receptor was
blocked by LE135 (1 mM). After 7 days, IgA levels were measured in
supernatant. (B) Similar as in A, but here in the presence of SB-431542
(5 mM) (or vehicle) alone to inhibit TGFb-specific signaling or together
with LE135. After 7 days, IgA levels were measured in supernatant. (C)
BM-DC and B cells were co-cultured as described, however the DC were
WT or deficient for iNOS (C57/Bl6 background). Data shown are mean +/
2 s.e.m from at least 3 pooled experiments * P,0.05, ** P,0.01, ***
P,0.001.
doi:10.1371/journal.pone.0059822.g004
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Figure 5. Ex vivo CTB pulsed DCs promote IgA responses in the lungs via RA and TGF-b. PBS, OVA (800 mg/80 ml/mouse), OVA+CTB (0.1 or
0.001 mg/80 ml) or CTB alone were instilled in lungs of naı¨ve mice. (A) After OVA challenge, lung B cells were isolated, cultured and restimulated by
LPS (10 mg/ml) for 7 days and IgA levels were determined (B) AF488-labeled CTB (and as a control Fitc-labeled OVA) was used. After 36 hrs, MedLN
and lung tissue were studied for the presence of AF488-positive cell populations: Dead cells are excluded based on FSc and SSc; AF488 positive cells
selected; migratory cDCs (MHCIIhi) subdivided into CD11b+ and CD11b- subsets; resident DCs (MHCIIint); CD11cloMHCIIlo cells, subdivided into pDC
IgA Induction by Cholera Toxin B-Dendritic Cells
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ALDH: 10–20% positive cells for both CD103+ and CD11b+ DCs,
but no differences were observed between the groups (data not
shown).
The findings that CTB targets mainly DCs and induces
increased IgA via upregulating the expression of the RA
synthesizing enzyme on CD11b+ DCs in vivo, directed us to
further study the role of RA and TGFb in the in vivo induction of
IgA in CD11b+ DCs. The numbers of CD11b+ DCs in lung
draining LNs are very low, and insufficient numbers of DCs could
be sorted from the LNs to perform adoptive transfer experiments.
Therefore, BM-DCs which are mainly of the CD11b+ type were
used for in vivo adoptive transfer experiments. As published
previously, DCs exposed ex-vivo to OVA+CTB and injected into
the airways of naı¨ve mice resulted in increased IgA levels in BAL
fluid, increased IgA production by ex vivo restimulated lung B cells,
and increased number of IgA+ cells in lung tissue, compared to
mice injected with unpulsed, OVA-pulsed or CTB-pulsed DCs
[8]. Using this system, the involvement of both TGF-b and RA in
CTB-driven IgA production was revealed, by blocking the
function of these factors in vivo. Anti-TGF-b antibody and RA
receptor blocking agent LE135 were administered one day before
until 3 days after the intratracheal administration of OVA +/2
CTB-pulsed DCs. After OVA aerosol challenge to boost
immunoglobulin production, both the percentage and the absolute
number of IgA+ cells in the lung were reduced in lung tissue of
mice treated with LE135 and anti-TGF-b compared to control
mice only receiving solvent and OVA+CTB pulsed DCs
(Figure 5e).
Discussion
DC-driven IgA induction has been demonstrated to be a unique
feature of mucosal DCs such as lamina propria or PP DCs in the
gut [23,24], expressing several IgA inducing factors, including RA,
TGF-b, iNOS, APRIL and/or BAFF [13]. Here we demonstrate
that CTB, in conjunction with MyD88-dependent TLR ligands,
can imprint non-mucosal BM-DCs to induce strong IgA responses
in naı¨ve B cells This involves partly similar IgA-inducing factors as
described for mucosal DC, as we identified a dominant positive
role for RALDH1 and TGF-b, but not for iNOS, BAFF and
APRIL. It has been shown, that also the mucosal factor RA can
enhance the IgA inducing capacity of non-mucosal BM-DC, by
increasing RALDH2 expression and TGF-b production and being
amplified by MyD88 signaling, similar to what we here observe for
CTB [19,25,26]. An interesting possibility might be that the
working mechanism of CTB can be explained via the induction of
enhanced RA expression by DCs which may affect DC function in
an autocrine loop.
Despite the widespread availability of retinol, RALDH expres-
sion is limited to certain cell types. DCs that are located in gut-
associated lymphoid tissue (GALT) and express RALDH2 are well
known for their RA production and IgA inducing ability. But
other DC subsets with RA producing capacity have been
described and expression of one of the aldehyde dehydrogenases,
RALDH1, 2 or 3, is essential for a cell to be able to catalyze the
oxidation of retinal into RA [15,27,28]. In lung DC, expression of
RALDH1 is more prominent like in our CTB-treated BM-DCs
[29]. The fact that we do not find differences in RALDH2
expression of cultured CTB exposed BM-DC, could be due to the
GMCSF which is used to generate the BM-DC in vitro. Yokota
et al showed that GMCSF is sufficient to markedly induce
RALDH2 expression in cultured BMDC, and this could overrule
the effect of CTB in our system [20]. Nevertheless, although
removal of GM-CSF for 24 hours during pulsing did result in
much lower gene expression profiles of RALDH2, we still did not
observe an upregulation for RALDH2, only RALDH1 (data not
shown), possibly explained by an irreversible effect of GM-CSF
stimulation on RALDH2 transcription. Furthermore, CTB only
induced similarly enhanced levels of RALDH1 as LPS+CTB,
while TGF-b was mostly increased in the LPS+CTB condition.
This suggests that a combined action of RALDH and TGFb is
necessary, like recently described by Feng et al for the IgA-
inducing activity of RA on BM-DCs [25] Therefore, CTB either
partly mimics the effects of RA by inducing similar mucosa-
associated factors or acts via the induction of RA itself in non-
mucosal DCs.
CTB binds to GM-1 ganglioside, which is present on many
different hematopoietic and structural cell types [16]. Despite this
wide expression pattern, we showed that CTB administered into
the airways mainly targeted DCs and that CTB-loaded DCs
migrated to the draining LNs (figure 5b). This finding is supported
by other studies in the skin, showing a specific recruitment of DCs
towards areas of CT administration [30,31]. In the lung of mice,
several DC subsets have been described: e.g. two major subsets of
conventional DCs have been defined based on their CD103 and
CD11b expression [32]. Very recently, it was published that
in vitro mouse CD11bhigh lung DC induce IgA more efficiently,
than CD103+ lung DC [33]. However, it was not clear by what
mechanisms this was induced, as the expression of BAFF, APRIL
or RALDH1 was not different between the two lung DC subsets.
In the gut, specialized DC subsets inducing TI IgA synthesis are
iNOS+TNF+ DCs (tipDCs) [34], and the recently described
CD11b+ DCs expressing TLR5 and not TLR4 [35]. Moreover,
CD103+ DCs, by producing RA and TGF-b, are responsible for
imprinting gut-homing molecules on B cells, and support IgA
synthesis [15,27,36,37]. Administration of CTB in the airways
results in increased IgA responses, and increased RA-producing
capacity as measured by higher ALDH enzyme activity of DC,
compared to control conditions. Although in the MedLN a larger
proportion of CTB-loaded DCs were CD11b2CD103+ than
CD11b+ (figure 5b), expression of ALDH was higher in CD11b+
DCs compared to in CD103+ DCs after CTB administration
(figure 5c). This in contrast to the gut, where the CD103+ DCs are
the ones that express higher levels of RALDH, and not the
CD11b+ DCs. Interestingly, and in line with our study, Guilliams
et al recently described that in the skin RA production and
tolerogenic functions were restricted to CD1032 DCs [38].
Furthermore, in the lung, it was suggested recently that CD11b+
DC are more potent in their capacity to induce IgA responses than
the CD103+ subset [33]. Thus, CD103 or CD11b may not be
specific markers for the identification of specialized DCs subsets
with IgA promoting capacity. Although, in our model the
(B220+) and alveolar macrophages (CD11b+) (C) As in B. Percentage of AF488-positive DC subsets total AF488+ cells in MedLN (D) After 36 hrs,
MedLN were isolated. ALDH enzyme activity of different DC subsets was determined using ALDEFLUOR assay, by flowcytometry. (E) BM-DC were
generated as described and pulsed with PBS, OVA (100 mg/ml), OVA+CTB (10 mg/ml) or CTB only (10 mg/ml) and the next day intratracheally injected
in naı¨ve mice. One day before until 3 days after DC instillation, mice were treated i.p with LE135 and anti-TGFb antibody (or isotype Ab and DMSO).
After one week, the mice were challenged by OVA for 3 consecutive days. One day after challenge, the number of IgA+ cells in digested lungs was
determined by flowcytometry. Data are mean +/2 s.e.m, of at least 2 individual experiments with 4 mice per group (for D: 12 mice per group, pooled
per 3 mice, resulting in 4 datapoints per group). # p = 0.10 * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0059822.g005
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increased ALDH activity on the CD11b+ DC subset, and the
increased IgA after transfer of (CD11b+) BM-DC, could suggest
that this subset is more important in driving CTB induced IgA
responses in the airways, we cannot rule out involvement of
CD103+ DCs nor other DC subsets. The role of different lung DC
subsets and their mechanism of driving humoral IgA responses
needs to be further investigated.
CTB can enhance phosphorylation of multiple signaling
molecules downstream of TLRs [39], but requires a MyD88-
dependent co-activation signal for its IgA inducing capacity.
MyD88 is an adaptor molecule downstream of many TLRs [40].
In the gut, DCs are constantly exposed to TLR ligands derived
from commensal bacteria, and these signals play a major role in
driving IgA responses [2,10,14]. Indeed in vitro priming of DCs by
different MyD88-dependent TLR ligands enhanced IgA produc-
tion by B cells, but not by MyD88-independent PRR-ligands, such
as Poly I:C, Zymosan and Curdlan (figure 2b). Although, CpG DC
induce some IgA response by B cells, CTB was not able to
enhance this effect. This might be explained by the endosomal
localization of TLR9, although this is also the case for TLR 7 and
8 (ligated by CL97) for which we did observe CTB-enhanced IgA
induction. Therefore an alternative explanation might be the
negative charge of CpG that may influence the IgA-inducing
instructions of CTB to the DC.
Importantly, CTB does not only enhance IgA induction by high
dose TLR-ligand primed DCs, but also initiates IgA production in
case of low dose exposure to MyD88-activating ligands. This is
particularly interesting, considering the thought that decreased or
altered microbial exposure associated with affluent life style allows
uncontrolled inflammatory responses against either innocuous or
self-antigens [41]. Indeed, Hilty et al compared the airway
microbiota of patients with asthma and controls, and found
disturbed microbiota in asthmatic airways [42]. Therefore CTB
may have potential in the clinic, by translating insufficient
microbial signals into enhanced, and putative protective, IgA
levels. In a mouse model, CTB was able to enhance protective
mucosal sIgA responses against aero-allergens [8]. Furthermore, in
some models CTB can also induce FoxP3+ regulatory T cell
responses in vivo when coupled to specific antigens [43]. Interest-
ingly, oral CTB has already been applied for treatment of Crohn’s
disease, reporting decreased disease activity scores [44], which
shows the potential use of CTB for hyperinflammatory diseases.
In conclusion, this study demonstrates that the prototypical
‘‘mucosal’’ adjuvant CTB promotes IgA responses by directly
instructing DCs to prime IgA responses in B cells, through
instructive signals normally found only in the mucosal environ-
ment. The CTB instructs mucosal DC priming best when TLR
ligands that employ the MyD88 signaling pathway are co-
administered. Like in the mucosal environment, CTB-induced
IgA induction by non-mucosal DCs, depends on RA and TGF-b.
Future studies on CTB are needed to investigate whether CTB
equally influences DC driven IgA responses in humans before this
work can be employed for boosting IgA responses to allergens in
humans.
Materials and Methods
Ethics Statement
Mice were housed under SPF-conditions at the animal facilities
of the Leiden University Medical Center in Leiden, the Nether-
lands. All animal studies were performed according to the
institutional guidelines and the experimental protocols described
in DEC-09028 were approved by the Ethics Committee for
Animal Experimentation of the University of Leiden, the Nether-
lands.
Animals
Female Balb/c and C57BL/6 mice (6–8 wks) were purchased at
Harlan, the Netherlands. MyD88-deficient mice were bred in
animal facility (UZ Ghent, Belgium). iNOS-deficient mice were
kindly provided by Dr. A Cauwels (VIB Ghent, Belgium).
Cell Preparation and in vitro Co-culture
BM-DCs were generated from bone marrow cells, as described
before [8], and cultured in RPMI 1640 medium containing
glutamax (GIBCO), 50 mM 2-mercaptopethanol Signa-Aldrich),
50 mg/ml gentamicin Invitrogen) or sodium-penicillin (Astellas
Pharma B.V), streptomycin (0,1 ug/ml, Sigma-Aldrich), and 5%
fetal bovine serum (TCM), supplemented with 20 ng/ml recom-
binant murine granulocyte macrophage-colony stimulating factor
(rmGM-CSF, (a gift from K. Thielemans, Vrije Universiteit
Brussel, Brussels, Belgium). After 8 days, DCs were pulsed
overnight with PBS or LPS (1 or 100 ng/ml) with or without
CTB (10 mg/ml, Sigma-Aldrich, St. Louis, MO). In specific
experiments, BM-DCs were pulsed with different TLR ligands
(Poly I:C 25 mg/ml, LPS 100 ng/ml, Flagellin 1 mg/ml, FLS1
10 mg/ml, Cl97 1 mg/ml, CpG 2.5 mg/ml) or C-type lectin
receptor ligands (CTL) (Zymozan 10 mg/ml, Curdlan 150 mg/
ml) with and without CTB. To isolate PP DCs, lymph nodes were
collected 10–12 days after i.p. injection with 6 million B16 Flt3-L
secreting melanoma cells [45] and digested by collagenase (type 3
filtered, Worthington) and DNAse I (Sigma-Aldrich). DCs were
isolated using CD11c microbeads (Miltenyi), with a purity of
.85% as confirmed by flowcytometry. The remaining cells
contained ,4% CD19+ B cells.
After overnight stimulation, these DCs (1*105) were washed and
co-cultured with B cells (1:1 ratio) and anti-mouse IgM F(ab’)2
(10 mg/ml; Jackson Immunoresearch, West Grove, PA) (adapted
from [18]) for 7 days. Murine B cells were isolated from spleens
using anti-CD19 microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) with a purity of around 95% as confirmed by
flowcytometry. For some experiments, chemical inhibitors were
added: RARb receptor antagonist LE135 (1 mM in DMSO, Tocris
Bioscience, Ellisville, MO), or TGFß signaling inhibitor (5 mM,
SB-431542, Sigma-Aldrich). Supernatant was collected and
immunoglobulin levels determined by ELISA.
In vivo Mouse Models
OVA (800 mg/mouse) +/2 CTB (0.001 or 0.1 mg/mouse,
Sigma-Aldrich, St. Louis, MO) intratracheal administration was
followed 10 days later by OVA aerosol challenge for 3 consecutive
days. One day after the last challenge, lungs were digested with
collagenase/DNAse, B cells isolated (CD19+ MACS isolation),
and restimulated with LPS (10 mg/ml) for 5 days. Supernatant was
collected and IgA production analysed by ELISA. Or AF488-
labeled recombinant CTB (10 mg per mouse, Molecular Probes,
Eugene, OR) or CTB (0.1 mg/mouse, Sigma-Aldrich, St. Louis,
MO) +/2 OVA (800 mg/mouse) was administered into the
airways. The lung draining lymph nodes and lungs were removed
after 36 hrs and digested using collagenase/DNAse [8]; AF488-
fluorescence of several cell types or aldehyde dehydrogenase
(ALDH) activity (using ALDEFLUOR assay kit, Stemcell Tech-
nologies, as described [38]) of DC subsets was studied by
flowcytometric staining.
Unpulsed, OVA- (100 mg/ml, containing LPS, Worthington
Biochemical Corp., Lakewood, NJ) or OVA+CTB (10 mg/ml) -
pulsed BM-DCs (1*106 cells) were administered into the airways,
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as described [46], while (1 day before until 3 days after) TGFb
and retinoic acid activity was neutralized by i.p injection of LE135
and aTGFb antibody (or vehicle/isotype control Ab). This was
followed 10 days later by OVA aerosol challenge on three
consecutive days. One day after the last challenge lungs were
isolated, digested using collagenase/DNAse and analysed for
presence of IgA positive B cells by flowcytometry.
RNA Extraction and RT-PCR
BM-DCs were pulsed for 24 hrs and cell pellets were snap-
frozen. Subsequently, total RNA was isolated, followed by cDNA
synthesis, as described [8]. Quantitative real-time RT-PCR was
performed using Brilliant SYBR Green (Stratagene, Santa Clara,
CA) in an ABI 7500 RT-PCR machine (Applied Biosystems).
Expression was normalized to the housekeeping gene GAPDH,
and presented relative to conventional unpulsed BM-DCs.
Sequences of primers were used as described [14]. In addition,
RALDH2 expression was studied using the following primer
sequences: 59-AGC CCA TTG GAG TGT GT-39 and 59-CCA
GCC TCC TTG ATG AG-39.
Immunoglobulin Measurements
Ig levels (IgA/IgG1/IgG2a/IgE/IgM) were measured by
ELISA (BD Biosciences). Detection limit was 2 ng/ml for all Igs.
Statistical Analysis
To study whether there is a general difference between 3 or
more groups, first ANOVA test was performed, followed by
Bonferoni post hoc test to compare specific groups or the Mann-
Whitney U t-test was used to compare two individual groups. P
values less than 0.05 were considered significant. P-values less than
0.05, 0.01 or 0.001 are indicated by one, two or three asterisks,
respectively.
Supporting Information
Figure S1 BM-DCs were generated by culture in GM-
CSF (A and C) or Flt3-L (B). At day 8, DCs were pulsed with
medium, LPS (1 ng/ml), LPS+CTB (10 mg/ml) or CTB only.
Thereafter, cells were washed and co-cultured with (A/C) naı¨ve
CD432 B cells (ratio 1:1), or (B/C) with CD19+ B cells and anti-
IgG/IgM (10 mg/ml). Total CD19+ B cells were retrieved by
positive selection with CD19 microbeads from splenocytes, while
naı¨ve B cells were collected after negative isolation with the
CD432 naı¨ve B cell isolation kit (both from Miltenyi). After 7 days,
supernatant was collected and IgA levels were measured by
ELISA. (C) 48 hrs after the start of the co-culture, B cells were
collected and cell pellets snapfrozen. After RNA extraction, RT-
QPCR was performed for AID (Primer sequence Forward: 59-
TCC TGC TCA CTG GAC TTC GG-39, Reverse: 59-GTG
AAC CAG GTG ACG CGG TA-39) and GAPDH gene
expression in CD432 en total CD19+ B cells, that were co-
cultured with GM-CSF-generated BM-DCs. Mean+sem of 3 or 4
individual experiments are shown * P,0.05, ** P,0.01, ***
P,0.001, # P = 0.100.
(PDF)
Figure S2 Increased LAP expression on LPS+CTB
treated BM-DCs. BM-derived DCs were cultured for 8
days with GMCSF, pulsed overnight with PBS, LPS
(1 ng/ml) +/2 CTB (10 mg/ml) or CTB alone. LAP
expression of PFA fixed and Brefeldin A treated pulsed DCs, by
FACS. Geomean is displayed, relative to the expression of
unpulsed BM-DC. Mean+sem of 4 individual experiments are
shown * P,0.05, ** P,0.01, *** P,0.001.
(PDF)
Figure S3 Role of BAFF and APRIL in IgA induction by
CTB-primed DCs. BM-derived DCs were cultured and pulsed
as described in the legend of figure 1, and then co-cultured with
splenic CD19+ B cells (ratio 1:1) and anti-IgM Fab-fragments
(10 mg/ml). After 7 days, IgA levels were determined by ELISA.
(A) During co-culture either blocking antibodies against BAFF
(0.2 mg/ml, R&D systems), BAFFR3 (2 mg/ml, R&D systems), or
isotype controls were added. (B) BM-DCs from B6129S2F1 mice
were generated, pulsed and co-cultured with splenic TACI/
BCMA2/2 B cells (on a B6129S2F1 background) as described.
Data from one representative experiment out of 4 are shown. *
P,0.05, ** P,0.01, *** P,0.001.
(PDF)
Figure S4 OVA Worthington contains sufficient LPS to
induce IgA in synergy with CTB. BM-derived DCs were
cultured, and pulsed overnight with PBS, OVA (100 mg/ml,
containing LPS), LPS free OVA (100 mg/ml, Seikagaku [de Heer,
J ex Med 2004]) or LPS (1 ng/ml), either or not in combination
with CTB (10 mg/ml) or CTB alone, thereafter cultured with B
cells for 7 days as described. Supernatant was collected and IgA
production measured by ELISA. Data from one representative
experiment out of 2 are shown. * P,0.05, ** P,0.01, ***
P,0.001.
(PDF)
Figure S5 Representative ALDEFLUOR vs CD11c plots
of figure 5d are shown for (A) CD11b+ or (B) CD103+
migratory DCs from lung draining LNs.
(PDF)
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